Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Nov;112(11):1750-1751.
doi: 10.1038/ajg.2017.362.

Response to Miner et al

Affiliations
Comment

Response to Miner et al

Mark G Currie et al. Am J Gastroenterol. 2017 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Guarantor of the article: Jeffrey M. Johnston, MD.

Specific author contributions: M.G.C., S.J.S., H.A.S., and J.M.J. assisted in the interpretation of the data and critical revision of the letter for important intellectual content.

Financial support: This letter was funded by Allergan, plc and Ironwood Pharmaceuticals.

Potential competing interests: Mark G. Currie is an employee of and owns stock/stock options in Ironwood Pharmaceuticals. Jeffrey M. Johnston is a consultant for Ironwood Pharmaceuticals and owns stock/stock options in the company. Steven J. Shiff is an employee of and owns stock/stock options in Allergan plc. Harvey A. Schneier has served as a consultant to Allergan, plc.

Comment in

  • Response to Currie et al.
    Miner PB. Miner PB. Am J Gastroenterol. 2017 Nov;112(11):1751. doi: 10.1038/ajg.2017.384. Am J Gastroenterol. 2017. PMID: 29109504 No abstract available.

Comment on

References

    1. Miner PB, Koltun WD, Wiener GJ et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol 2017;112:613–621. - PMC - PubMed
    1. Lembo AJ, Schneier HA, Shiff SJ et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527–536. - PubMed
    1. FDA Summary basis of approval for plecanatide: application # 208745Orig1s000, Medical Review(s) FDA CDER https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208745Orig1s000R....